Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Osemitamab · TST-001, MSB-018

Monoclonal antibody · Kills target cells, directed at Claudin-18.2 (CLDN18) · developed by Transcenta Therapeutics Co.

Phase 1/2 Most advanced trial

1 Registered trials

What is Osemitamab?

Osemitamab is a humanized IgG1 monoclonal antibody directed against Claudin-18.2, a tumor-associated antigen overexpressed on gastric and other cancers. It kills CLDN18.2-expressing tumor cells through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It is studied in gastric, gastroesophageal-junction, and pancreatic cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: TST-001, MSB-018
Drug type: Monoclonal antibody
Targets: Claudin-18.2 (CLDN18)
Mechanism: Kills target cells, directed at Claudin-18.2 (CLDN18)
Pathways: ADCC, CDC, cell proliferation inhibition
Therapy area: Oncology
Developer: Transcenta Therapeutics Co., Ltd.
In trials of: BMY
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: H14V1A2F4D

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04396821	Phase 1/2	Advanced Cancer	Active not recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerGastric CancerGastroesophageal-junction CancerPancreatic Cancer

Other drugs acting on CLDN18

Sonesitatug Vedotin Phase 2 Spevatamig Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z